$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000106282222000042 Filed on November 09, 2022

Income Statement

Concept	2022 Q4	2022 Q3
Revenue	$28.00K	$39.00K
YoY Change	100.0%	69.57%
Cost Of Revenue		$0.00
YoY Change
Gross Profit		$39.00K
YoY Change		69.57%
Gross Profit Margin		100.0%
Selling, General & Admin	$16.33M	$12.58M
YoY Change	84.59%	72.22%
% of Gross Profit		32248.72%
Research & Development	$13.98M	$10.56M
YoY Change	-15.28%	-32.68%
% of Gross Profit		27069.23%
Depreciation & Amortization	$103.0K	$108.0K
YoY Change	-8.04%	6.93%
% of Gross Profit		276.92%
Operating Expenses	$30.31M	-$23.13M
YoY Change	19.58%	-200.65%
Operating Profit		-$23.10M
YoY Change		0.58%
Interest Expense	-$1.103M	$864.0K
YoY Change	273.9%	405.26%
% of Operating Profit
Other Income/Expense, Net	$887.0K	$572.0K
YoY Change	6235.71%	5100.0%
Pretax Income	-$30.49M	-$23.39M
YoY Change	19.07%	1.15%
Income Tax
% Of Pretax Income
Net Earnings	-$30.49M	-$23.39M
YoY Change	19.07%	1.15%
Net Earnings / Revenue	-108907.14%	-59966.67%
Basic Earnings Per Share		-$0.13
Diluted Earnings Per Share	-$0.16	-$133.7K
COMMON SHARES
Basic Shares Outstanding	188.7M shares	183.6M shares
Diluted Shares Outstanding		174.9M shares

Balance Sheet

Concept	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$138.4M	$136.2M
YoY Change	59.5%	12.64%
Cash & Equivalents	$46.35M	$18.83M
Short-Term Investments	$92.01M	$117.4M
Other Short-Term Assets	$2.481M	$2.821M
YoY Change	14.65%	-7.93%
Inventory	$0.00
Prepaid Expenses
Receivables	$28.00K	$39.00K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$140.9M	$139.1M
YoY Change	58.42%	12.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.071M	$932.0K
YoY Change	76.11%	-28.91%
Goodwill	$44.54M	$44.54M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.819M	$7.147M
YoY Change	200.53%	189.24%
Total Long-Term Assets	$53.43M	$52.62M
YoY Change	11.35%	8.89%
TOTAL ASSETS
Total Short-Term Assets	$140.9M	$139.1M
Total Long-Term Assets	$53.43M	$52.62M
Total Assets	$194.3M	$191.7M
YoY Change	41.92%	11.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.40M	$9.427M
YoY Change	13.58%	12.97%
Accrued Expenses	$12.78M	$9.018M
YoY Change	-1.5%	-36.53%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$23.17M	$18.45M
YoY Change	4.74%	-46.14%
LONG-TERM LIABILITIES
Long-Term Debt	$48.58M	$23.78M
YoY Change
Other Long-Term Liabilities	$5.424M	$5.438M
YoY Change	355.8%	267.18%
Total Long-Term Liabilities	$5.424M	$29.22M
YoY Change	355.8%	1873.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.17M	$18.45M
Total Long-Term Liabilities	$5.424M	$29.22M
Total Liabilities	$77.18M	$47.67M
YoY Change	231.02%	33.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.590B	-$1.559B
YoY Change	6.85%	6.64%
Common Stock	$189.0K	$189.0K
YoY Change	26.0%	26.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.061M	$2.061M
YoY Change	-72.59%	-72.59%
Treasury Stock Shares	488.0K shares	488.0K shares
Shareholders Equity	$117.1M	$144.0M
YoY Change
Total Liabilities & Shareholders Equity	$194.3M	$191.7M
YoY Change	41.92%	11.23%

Cashflow Statement

Concept	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	-$30.49M	-$23.39M
YoY Change	19.07%	1.15%
Depreciation, Depletion And Amortization	$103.0K	$108.0K
YoY Change	-8.04%	6.93%
Cash From Operating Activities	-$21.57M	-$19.44M
YoY Change	-5.52%	13.35%
INVESTING ACTIVITIES
Capital Expenditures	$1.246M	-$4.000K
YoY Change	-5517.39%	-98.12%
Acquisitions
YoY Change
Other Investing Activities	$25.42M	-$77.19M
YoY Change	315.43%	41179.14%
Cash From Investing Activities	$24.17M	-$77.20M
YoY Change	296.56%	19199.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	24.91M	94.02M
YoY Change	-320.0%	375.3%
NET CHANGE
Cash From Operating Activities	-21.57M	-19.44M
Cash From Investing Activities	24.17M	-77.20M
Cash From Financing Activities	24.91M	94.02M
Net Change In Cash	27.51M	-2.616M
YoY Change	-198.07%	-217.26%
FREE CASH FLOW
Cash From Operating Activities	-$21.57M	-$19.44M
Capital Expenditures	$1.246M	-$4.000K
Free Cash Flow	-$22.82M	-$19.43M
YoY Change	0.04%	14.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-30111
	dei	Entity Registrant Name EntityRegistrantName	Lexicon Pharmaceuticals, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	76-0474169
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2445 Technology Forest Blvd.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	11th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	The Woodlands
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77381
	dei	City Area Code CityAreaCode	281
	dei	Local Phone Number LocalPhoneNumber	863-3000
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
	dei	Trading Symbol TradingSymbol	LXRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	188725743	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18834000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64065000	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	117369000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	22678000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	39000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14000	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	2821000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2164000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	139063000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	88921000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5177000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4853000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	932000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1176000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	44543000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	44543000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7147000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2269000	usd
CY2022Q3	us-gaap	Assets Assets	191685000	usd
CY2021Q4	us-gaap	Assets Assets	136909000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9427000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9152000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9018000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12972000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	18445000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22124000	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	23784000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5438000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1190000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	47667000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	23314000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	189214000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	150082000	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	189000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	150000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1705607000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1608749000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1559226000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1487776000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-491000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10000	usd
CY2022Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	488000	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1165000	shares
CY2022Q3	us-gaap	Treasury Stock Value TreasuryStockValue	2061000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	7518000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	144018000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	113595000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	191685000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	136909000	usd
CY2022Q3	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	39000	usd
CY2021Q3	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	23000	usd
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	111000	usd
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	284000	usd
CY2022Q3	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	939000	usd
CY2021Q3	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1138000	usd
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	3069000	usd
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	3608000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10557000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15682000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38839000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38548000	usd
CY2022Q3	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	1709000	usd
CY2021Q3	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	1574000	usd
	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	5183000	usd
	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	4741000	usd
CY2022Q3	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	12577000	usd
CY2021Q3	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	7303000	usd
	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	31754000	usd
	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	23496000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	-23134000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	22985000	usd
	us-gaap	Operating Expenses OperatingExpenses	70593000	usd
	us-gaap	Operating Expenses OperatingExpenses	62044000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-23095000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-22962000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-70482000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-61760000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	864000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	171000	usd
	us-gaap	Interest Expense InterestExpense	1677000	usd
	us-gaap	Interest Expense InterestExpense	507000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	572000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	709000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	120000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-23387000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-23122000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-71450000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-62147000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	174904000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145820000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	157984000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	144558000	shares
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-341000	usd
CY2021Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-481000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23728000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23122000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-71931000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-62146000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	156371000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2851000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	548000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16399000	usd
CY2021Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	2675000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	11000	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	152547000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2786000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	31000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-10000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	137233000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2712000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	658000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	19123000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	136603000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	113595000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2772000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	698000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	0	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	864000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-23476000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-27000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	92698000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2832000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-24587000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-113000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	70830000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2648000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	94268000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-23387000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-341000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	144018000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-71450000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-62147000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	324000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	180000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8252000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8349000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	396000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	46000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	26000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-372000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	470000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1985000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-329000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-459000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4637000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-13433000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67282000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-64189000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	80000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1198000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	133363000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	28880000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	38191000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	26092000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-95252000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3986000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	94268000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	36705000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	864000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2675000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	23899000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	117303000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34030000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-45231000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34145000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64065000	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126263000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18834000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92118000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1281000	usd
	us-gaap	Interest Paid Net InterestPaidNet	307000	usd
CY2022Q3	lxrx	Initial Recognition Of Right Of Use Asset InitialRecognitionOfRightOfUseAsset	5206000	usd
CY2021Q3	lxrx	Initial Recognition Of Right Of Use Asset InitialRecognitionOfRightOfUseAsset	1704000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	698	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	usd
	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	6321	usd
	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	0	usd
	us-gaap	Business Exit Costs1 BusinessExitCosts1	1500	usd
	us-gaap	Business Exit Costs1 BusinessExitCosts1	0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span>
CY2022Q3	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	1184000	usd
CY2021Q4	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	3669000	usd
CY2022Q3	lxrx	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	5709000	usd
CY2021Q4	lxrx	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	5711000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1406000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1089000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	719000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2503000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	9018000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	12972000	usd
CY2021Q1	lxrx	Lexicon Incremental Borrowing Rate LexiconIncrementalBorrowingRate	9
CY2022Q3	lxrx	Lexicon Incremental Borrowing Rate LexiconIncrementalBorrowingRate	9.7
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	18834000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	117369000	usd
CY2022Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	136203000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	64065000	usd
CY2021Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	22678000	usd
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	86743000	usd
CY2022Q3	lxrx	Oxford Loan Facility OxfordLoanFacility	150000000	usd
CY2025	lxrx	A2027 Oxford Principal Payments A2027OxfordPrincipalPayments	8700000	usd
CY2026	lxrx	A2026 Oxford Principal Payments A2026OxfordPrincipalPayments	13000000	usd
CY2027	lxrx	A2027 Oxford Principal Payments A2027OxfordPrincipalPayments	4800000	usd
CY2022Q1	lxrx	Term Loan A TermLoanA	25000000	usd
CY2022Q4	lxrx	Term Loan B TermLoanB	25000000	usd
CY2023Q2	lxrx	Term Loan C TermLoanC	50000000	usd
CY2024Q4	lxrx	Term Loan D TermLoanD	50000000	usd
CY2022Q3	lxrx	Term Loan Ab Warrant TermLoanABWarrant	0.0350
CY2022Q3	lxrx	Term Loan C Warrant TermLoanCWarrant	0.0175
CY2022Q3	lxrx	Term Loan D Warrant TermLoanDWarrant	0.00875
CY2022Q1	lxrx	Term Loan A Warrants Number TermLoanAWarrantsNumber	420673	shares
CY2022Q1	lxrx	Term Loan A Warrant Exercise Price TermLoanAWarrantExercisePrice	2.08
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	700000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	700000	usd
CY2022Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0790
CY2022Q3	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.0801
	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.1045
CY2022Q3	lxrx	Final Payment With No Extention FinalPaymentWithNoExtention	0.06	rate
CY2022Q3	lxrx	Final Payment With Extention FinalPaymentWithExtention	0.07	rate
CY2022Q3	lxrx	Term Loan A Final Payment TermLoanAFinalPayment	1500000	usd
CY2022Q3	lxrx	Term Loan A Net Cash Receipt TermLoanANetCashReceipt	24200000	usd
CY2022Q3	lxrx	Term Loan A Debt Issuance Costs TermLoanADebtIssuanceCosts	400000	usd
CY2022Q3	lxrx	Oxford Facility Fee OxfordFacilityFee	500000	usd
CY2022Q3	lxrx	Term Loan A Final Payment TermLoanAFinalPayment	1500000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	700000	usd
CY2022Q3	lxrx	Oxford Amendment Fee OxfordAmendmentFee	300000	usd
CY2022Q3	lxrx	Term Loan A Debt Discount TermLoanADebtDiscount	2700000	usd
	lxrx	Term Loan A Interest Expense TermLoanAInterestExpense	1600000	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	23800000	usd
CY2014Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	87500000	usd
CY2014Q4	lxrx	Conv Debt Instrument Interest Rate Stated Percentage ConvDebtInstrumentInterestRateStatedPercentage	0.0525
CY2020Q3	lxrx	Convertible Debt Exchange Total Principal Amount ConvertibleDebtExchangeTotalPrincipalAmount	75800000	usd
CY2021Q4	lxrx	Convertible Debt Exchange Remaining Notes ConvertibleDebtExchangeRemainingNotes	11600000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7100000	usd
CY2022Q3	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	1400000	usd
CY2022Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	5400000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	292000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	805000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1378000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1219000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	865000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	6525000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11084000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4240000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	6844000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1406000	usd
CY2022Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	5438000	usd
CY2021Q1	lxrx	Shares Sold In January2021 Atm Offering SharesSoldInJanuary2021ATMOffering	2000000	shares
CY2021Q1	lxrx	Share Price In January2021 Atm Offering SharePriceInJanuary2021ATMOffering	8.463	shares
CY2021Q1	lxrx	Proceeds From January2021 Atm Offering ProceedsFromJanuary2021ATMOffering	16400000	usd
CY2021Q3	lxrx	Shares Sold In September2021 Atm Offerring SharesSoldInSeptember2021ATMOfferring	4176953	shares
CY2021Q3	lxrx	Share Price In September2021 Atm Offerring SharePriceInSeptember2021ATMOfferring	4.732	usd
CY2021Q3	lxrx	Proceeds From September2021 Atm Offering ProceedsFromSeptember2021ATMOffering	19.1	usd
CY2022Q3	lxrx	Shares Sold In July2022 Offering SharesSoldInJuly2022Offering	39100000	shares
CY2022Q3	lxrx	Share Price In July2022 Offering SharePriceInJuly2022Offering	2.50	usd
CY2022Q3	lxrx	Proceeds From July2022 Offering ProceedsFromJuly2022Offering	94300000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001062822-22-000042-index-headers.html	Edgar Link	pending
0001062822-22-000042-index.html	Edgar Link	pending
0001062822-22-000042.txt	Edgar Link	pending
0001062822-22-000042-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lxrx-20220930.htm	Edgar Link	pending
lxrx-20220930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
lxrx-20220930_cal.xml	Edgar Link	unprocessable
lxrx-20220930_def.xml	Edgar Link	unprocessable
lxrx-20220930_lab.xml	Edgar Link	unprocessable
lxrx-20220930_pre.xml	Edgar Link	unprocessable
lxrx-20220930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2022 Q4 Form 10-Q Financial Statement

#000106282222000042 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2022 Q4 Form 10-Q Financial Statement

#000106282222000042 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx